ANDA 203129, held by Fresenius Kabi USA. Dexamethasone Sodium Phosphate.
As of Nov 21, 2026, ANDA 203129 (Dexamethasone Sodium Phosphate), held by Fresenius Kabi USA, was first approved by FDA on Sep 30, 2015, with 4 approved supplements and 0 published complete response letters.
INDICATIONS A. Intravenous or intramuscular administration. When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 30, 2015 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Dexamethasone Sodium PhosphateEQ 4MG PHOSPHATE/ML · injectable;injection | Dexamethasone Sodium Phosphate | Rx |
| Jun 5, 2024 | Supplement 9Labeling · Standard review | Approved | None posted |
| Jan 21, 2022 | Supplement 7Manufacturing · Standard review | Approved | None posted |
| Jul 28, 2020 | Supplement 2Labeling · Standard review | Approved | None posted |
| Aug 9, 2016 | Supplement 1Manufacturing | Approved | None posted |
| Sep 30, 2015 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters